Biopharmaceutical

Innovent Biologics released its 2024 ESG Report outlining a five-pillar strategy—Excellent Governance, Advancing Public Health, Uncompromising Quality, Empowering Talent, and Sustainable Ecology. Achieving an MSCI AAA ESG rating (the only Chinese biotech recipient), it aligned with UN SDGs, expanded board diversity, and distributed RMB 3.6 billion in medicines to 200,000+ patients. The company maintained 100% GMP compliance, reduced energy use by 29%, saved 51,100 tons of water annually, and achieved 96.8% employee retention with 44.2% women in management roles. Its pipeline includes 13 orphan drugs and three New Drug Applications under review, underscoring its dual focus on innovation and sustainability.